XCF Global Inc: Phillips 66 to End Supply and Offtake Agreement with New Rise Renewables Reno Starting May 1, 2026 - SEC Filing
Supply Termination: Global Inc. has announced the termination of its supply agreement with New Riser Renewables, effective May 1, 2026.
Offtake Agreement: The termination also includes an offtake agreement, indicating a significant shift in their business relationship.
Trade with 70% Backtested Accuracy
Analyst Views on SAFX
About SAFX
About the author


- Financial Evaluation: Discussions are ongoing regarding the financial impact of evaluating notices.
- Involvement of Phillips: The evaluation process includes consultations with Phillips, indicating a collaborative approach.

Supply Termination: Global Inc. has announced the termination of its supply agreement with New Riser Renewables, effective May 1, 2026.
Offtake Agreement: The termination also includes an offtake agreement, indicating a significant shift in their business relationship.

Global Renewable Fuel Tolling Agreement: Global Inc. has entered into a renewable fuel tolling agreement with BGN, effective April 9, 2026.
SEC Filing: The details of this agreement have been filed with the SEC, indicating compliance with regulatory requirements.
- Earnings Highlights: XCF Global, Inc. reported a FY GAAP EPS of $0.52, indicating stable profitability amidst market challenges, which may reassure investors about the company's financial health.
- Revenue Performance: The company achieved revenue of $20.82 million, showing growth compared to the previous year, reflecting its competitive position in the market and sustained customer demand, which enhances confidence in future growth.
- Quant Rating Insight: Seeking Alpha's Quant Rating on XCF Global, Inc. provides an in-depth analysis of the company's financial health, aiding investors in understanding its market positioning and potential investment value.
- Historical Data Context: The historical earnings data for XCF Global, Inc. offers crucial context for analyzing its long-term performance, allowing investors to assess growth trends and future prospects.
- Earnings Beat: The Oncology Institute reported a Q4 loss of 6 cents per share, outperforming the analyst consensus estimate of a 9-cent loss, indicating improvements in cost management and operational efficiency, which boosts market confidence in its future profitability.
- Sales Growth: The company achieved quarterly sales of $141.957 million, exceeding the analyst consensus of $139.775 million, reflecting positive progress in market demand and product promotion, thereby strengthening its market position in oncology treatment.
- Stock Surge: Shares of The Oncology Institute jumped 14.7% to $3.01 in pre-market trading, demonstrating a positive investor reaction to the financial results, which may attract more investor interest in its future developments.
- Increased Market Confidence: The better-than-expected performance not only enhances investor confidence but may also prompt analysts to reassess the company's long-term growth potential, potentially influencing future stock price movements and market performance.







